VEGFA and age-related macular degeneration: Intravitreal injection (IVI) of anti-vascular endothelial growth factor (VEGF) agents has become the standard of care for a variety of retinal diseases, including neovascular age-related macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV) [1,2,3,4,5,6,7,8,9].